Can miRNA testing detect brain cancer?

Brain cancers (including glioblastoma and other gliomas) are known to overexpress miR-21-5p, which is one of the three markers measured by OncuraKit. Glioblastoma in particular shows among the highest miR-21 overexpression of any cancer type. While OncuraKit's primary validated targets are six cancer types (prostate, colorectal, pancreatic, ovarian, lung, breast), the Yenos platform is expected to provide a signal for brain cancers. This is clinically significant because no current blood-based MCED test is validated for brain cancer detection — blood-brain barrier limitations restrict ctDNA from entering circulation efficiently. Urine-based miRNA detection may bypass this limitation. However, brain cancer is not yet among the formally validated indications of OncuraKit.